Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CMS to make 100% of claims data public

This article was originally published in The Gray Sheet

Executive Summary

Researchers will soon get a gift from Medicare - they'll be able to order selections of data from up to 100% of claims. Steve Phurrough, CMS Coverage & Analysis Group director, told an audience at the Transcatheter Cardiovascular Therapeutics meeting Oct. 25 in Washington, D.C., that the database will include all Medicare claims data, beginning with 2005, including inpatient, outpatient, nursing home and durable medical equipment data. "You will be able as a researcher to say to us, 'I want to see all your data on MI, or kidney stones,' whatever it is that you want, and it will be 100% of our claims," he said. At present, researchers can only request a selection of about 5% of the data. Phurrough hopes that with expanded availability, mandated by the Medicare Modernization Act, CMS will see more clinical data that can be applied directly to the Medicare population...

You may also be interested in...

Recent eMDR Change By FDA Asks Adverse Event Reporters About Third-Party Servicers

The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.

Experts: HHS Review Proposal May Free Industry From Regulatory Red Tape

Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.

Commercial Partner Sought For Nasal Spray Claimed To ‘Prevent’ COVID-19

A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts